RenovoRx Unveils Promising Phase III Data on TAMP Platform for Pancreatic Cancer at ASCO GI 2026

Reuters01-08

RenovoRx Unveils Promising Phase III Data on TAMP Platform for Pancreatic Cancer at ASCO GI 2026

RenovoRx Inc. has announced that new clinical data from a pharmacokinetic $(PK)$ and pharmacodynamic sub-study of its ongoing Phase III TIGeR-PaC clinical trial will be presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2026 (ASCO GI). The abstract, led by Dr. Paula M. Novelli of the University of Pittsburgh Medical Center, reports results from a study comparing intra-arterial gemcitabine $(IAG)$ delivered via the Trans-Arterial Micro-Perfusion (TAMP) therapy platform with standard intravenous gemcitabine in patients with locally advanced pancreatic cancer. The study analyzed systemic drug exposure and peak plasma concentrations in 16 patients across six clinical sites.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9622085-en) on January 08, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601362181?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-08 21:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601362181","market":"us","top_or_hot":-1,"title":"RenovoRx Unveils Promising Phase III Data on TAMP Platform for Pancreatic Cancer at ASCO GI 2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      RenovoRx Unveils Promising Phase III Data on TAMP Platform for Pancreatic Cancer at ASCO GI 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/RNXT\">RenovoRx Inc</a>. has announced that new clinical data from a pharmacokinetic <a href=\"https://laohu8.com/S/PK\">$(PK)$</a> and pharmacodynamic sub-study of its ongoing Phase III TIGeR-PaC clinical trial will be presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2026 (ASCO GI). The abstract, led by Dr. Paula M. Novelli of the University of Pittsburgh Medical Center, reports results from a study comparing intra-arterial gemcitabine <a href=\"https://laohu8.com/S/IAG\">$(IAG)$</a> delivered via the Trans-Arterial Micro-Perfusion (TAMP) therapy platform with standard intravenous gemcitabine in patients with locally advanced pancreatic cancer. The study analyzed systemic drug exposure and peak plasma concentrations in 16 patients across six clinical sites.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9622085-en) on January 08, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RenovoRx Unveils Promising Phase III Data on TAMP Platform for Pancreatic Cancer at ASCO GI 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRenovoRx Unveils Promising Phase III Data on TAMP Platform for Pancreatic Cancer at ASCO GI 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-08 21:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      RenovoRx Unveils Promising Phase III Data on TAMP Platform for Pancreatic Cancer at ASCO GI 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/RNXT\">RenovoRx Inc</a>. has announced that new clinical data from a pharmacokinetic <a href=\"https://laohu8.com/S/PK\">$(PK)$</a> and pharmacodynamic sub-study of its ongoing Phase III TIGeR-PaC clinical trial will be presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2026 (ASCO GI). The abstract, led by Dr. Paula M. Novelli of the University of Pittsburgh Medical Center, reports results from a study comparing intra-arterial gemcitabine <a href=\"https://laohu8.com/S/IAG\">$(IAG)$</a> delivered via the Trans-Arterial Micro-Perfusion (TAMP) therapy platform with standard intravenous gemcitabine in patients with locally advanced pancreatic cancer. The study analyzed systemic drug exposure and peak plasma concentrations in 16 patients across six clinical sites.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9622085-en) on January 08, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014021.USD","symbol_name":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL6xRBFs:1","article_id":"2601362181","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601362181","pubTimestamp":1767879011,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"RenovoRx Inc. has announced that new clinical data from a pharmacokinetic  and pharmacodynamic sub-study of its ongoing Phase III TIGeR-PaC clinical trial will be presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2026 . The abstract, led by Dr. Paula M. Novelli of the University of Pittsburgh Medical Center, reports results from a study comparing intra-arterial gemcitabine  delivered via the Trans-Arterial Micro-Perfusion  therapy platform with standard intravenous gemcitabine in patients with locally advanced pancreatic cancer. The study analyzed systemic drug exposure and peak plasma concentrations in 16 patients across six clinical sites.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4588":"碎股","BK4112":"金融交易所和数据","NDAQ":"纳斯达克OMX交易所","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","RNXT":"RenovoRx Inc","BK4539":"次新股","BK4585":"ETF&股票定投概念","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4139":"生物科技","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC"},"translate_title":"RenovoRx在ASCO GI 2026上公布了胰腺癌TAMP平台有希望的III期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"RNXT":0.9},"content_text":"RenovoRx Unveils Promising Phase III Data on TAMP Platform for Pancreatic Cancer at ASCO GI 2026\n    \n\nRenovoRx Inc. has announced that new clinical data from a pharmacokinetic $(PK)$ and pharmacodynamic sub-study of its ongoing Phase III TIGeR-PaC clinical trial will be presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2026 (ASCO GI). The abstract, led by Dr. Paula M. Novelli of the University of Pittsburgh Medical Center, reports results from a study comparing intra-arterial gemcitabine $(IAG)$ delivered via the Trans-Arterial Micro-Perfusion (TAMP) therapy platform with standard intravenous gemcitabine in patients with locally advanced pancreatic cancer. The study analyzed systemic drug exposure and peak plasma concentrations in 16 patients across six clinical sites.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9622085-en) on January 08, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601362181","isCrawlerRequest":true}